Search Result

Results for "

neutralization

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (4) Apoptosis (6) Autophagy (3) Bacterial (5) Biochemical Assay Reagents (6) c-Fms (2) c-Met/HGFR (1) Caspase (1) CMV (2) CXCR (3) Disulfidptosis (4) EGFR (1) Endogenous Metabolite (7) ERK (1) Factor VIIa (1) Factor Xa (3) Ferroptosis (5) FGFR (2) HBV (2) HIV (4) HSV (2) IFNAR (1) Influenza Virus (8) Interleukin Related (13) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) Liposome (1) PARP (1) PCSK9 (1) PD-1/PD-L1 (1) PDGFR (1) RABV (2) Reactive Oxygen Species (7) RSV (1) SARS-CoV (13) Survivin (1) TGF-β Receptor (3) Thrombin (2) TNF Receptor (3) Toll-like Receptor (TLR) (1) VEGFR (3)
By Research Areas:	Cancer (27) Cardiovascular Disease (6) Infection (41) Inflammation/Immunology (22) Metabolic Disease (6) Neurological Disease (8)
Oligonucleotides:	Nucleotides and their Analogs (1) Aptamers (2) mRNA (2) Antisense Oligonucleotides (2)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9945

Mepolizumab SB 240563	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P9945A

Mepolizumab (anti-IL5)	Interleukin Related	Inflammation/Immunology
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P9917

Tocilizumab 20+ Cited Publications Anti-Human IL6R, Humanized Antibody	Interleukin Related	Inflammation/Immunology Cancer
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .

HY-122907

JNJ4796	Influenza Virus	Infection
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) .

HY-B1092

Gluconate Calcium Calcium D-gluconate; Gluconic acid hemicalcium salt	Endogenous Metabolite	Others Cancer
Gluconate Calcium (Calcium D-gluconate) is a mineral supplement, manufactured by the neutralization of gluconic acid with lime or calcium carbonate.

HY-100561

Tempol 15+ Cited Publications 4-Hydroxy-TEMPO	Reactive Oxygen Species Autophagy	Cancer
Tempol is a general superoxide dismutase (SOD)-mimetic agent that efficiently neutralizes reactive oxygen species (ROS).

HY-157930

TP-2	Others	Cardiovascular Disease
TP-2, a caltrop-like multicationic small molecule, is an antidote that can completely neutralize both unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs). TP-2 is not only superior to protamine, has higher neutralization activity, but is also biocompatible .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-P4042

Hepatitis B Virus Receptor Binding Fragment hepatitis B peptide 4980	HBV	Infection Inflammation/Immunology
Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .

HY-P4020

2F5 epitope	HIV	Others
2F5 epitope, a peptide gp41 (659-671), comprises the entire epitope for one of the three known antibodies capable of neutralizing a broad spectrum of primary HIV-1 isolates and is the only such epitope that is sequential. 2F5 epitope is recognized by broadly neutralizing antibodies 2F5 .

HY-P99937

Elipovimab	HIV	Infection
Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells

HY-153235

COVID-19 Spike Protein mRNA-LNP	SARS-CoV Liposome	Infection
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein , suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

HY-P99347

Etesevimab CB 6; JS016	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .

HY-P99305

Metelimumab 1 Publications Verification CAT-192; Anti-TGFB1 Recombinant Antibody	TGF-β Receptor	Inflammation/Immunology
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .

HY-147392

CXCR2 antagonist 8	CXCR	Metabolic Disease
CXCR2 antagonist 8 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research .

HY-107911

Protamine sulfate 1 Publications Verification	Thrombin	Metabolic Disease
Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer .

HY-P99584

Suvizumab KD-247	HIV	Infection
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1_MN, HIV-1_SF2 and HIV-1_89.6 with IC₅₀ values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .

HY-D0871

CHES N-Cyclohexyltaurine	Biochemical Assay Reagents	Others Cancer
CHES (N-Cyclohexyltaurine) is a zwitterionic buffer. CHES can bind to hemagglutinin (HA) emulating with sialic acid (SA) and receptor binding site (RBS)-targeting broadly neutralizing antibodies .

HY-B1610I

Sodium citrate dihydrate, for molecular biology Trisodium citrate dihydrate, for molecular biology	Biochemical Assay Reagents	Others
Sodium citrate dihydrate, for molecular biology is an antacid used in studies to neutralize gastric acid. Sodium citrate dehydrate is often used to prepare biological buffers and can be used in molecular biology research .

HY-P99703

Libivirumab 17.1.41	HBV	Infection
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC₅₀s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .

HY-P5851

AaHI	Biochemical Assay Reagents	Neurological Disease
AaHI is a neurotoxin that can be obtained from the venom of the North African scorpion Androctonus australis hector. AaHI can be used as a tool for the development of active substances with toxin-neutralizing capabilities .

HY-P9927

Secukinumab 1 Publications Verification AIN457	Interleukin Related	Inflammation/Immunology Cancer
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-P99307

Namilumab AMG-203; Anti-Human CSF2 Recombinant Antibody	c-Fms	Inflammation/Immunology
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .

HY-100561S1

Tempol-d17 4-Hydroxy-TEMPO-d₁₇	Autophagy Reactive Oxygen Species	Cancer
Tempol-d₁₇ is the deuterium labeled Tempol[1]. Tempol is a general superoxide dismutase (SOD)-mimetic agent that efficiently neutralizes reactive oxygen species (ROS)[2][3].

HY-P99947

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

HY-P99889

Romlusevimab BRII-198	SARS-CoV	Infection
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

HY-P99900

Sevirumab MSL-109	CMV	Infection
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC₅₀ of 0.3 μg/mL .

HY-P99811

Rafivirumab CR57	RABV	Infection
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .

HY-100561S

Tempol-d17,15N 4-Hydroxy-TEMPO-d₁₇,¹⁵N	Autophagy Reactive Oxygen Species	Cancer
Tempol-d₁₇, ¹⁵N is the deuterium labeled Tempol[1]. Tempol is a general superoxide dismutase (SOD)-mimetic agent that efficiently neutralizes reactive oxygen species (ROS)[2][3].

HY-P2920

Protamine from salmon	Biochemical Assay Reagents Thrombin Bacterial	Infection Cardiovascular Disease
Protamine from salmon is a biochemical agent with antioxidant, antiheparin and antimicrobial activities. Protamine from salmon neutralizes the anticoagulant effect of heparin, thereby preventing the formation of antithrombin complexes in canine samples pretreated with heparin in vitro .

HY-105240

Delparantag PMX-60056	Factor Xa	Cardiovascular Disease
Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH .

HY-P99792

Ormutivimab NM57; rhRIG	RABV	Infection
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .

HY-Y0319B

Acetic acid potassium 99% 2 Publications Verification	Endogenous Metabolite	Infection
Acetic acid potassium 99% is a potassium salt employed to replenish electrolytes, for restoration of water-electrolyte balance. Acetic acid potassium 99% can employ in DNA and protein purification. Acetic acid potassium 99% has been used to prepare neutralizing solution for alkaline lysis of bacteria .

HY-P99750

Navivumab CT-P23	Influenza Virus	Infection
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .

HY-160041A

Olaptesed pegol sodium	CXCR	Cancer
Olaptesed pegol sodium A pegylated-based L-oligoribonucleotide aptamer targeting CXCL12. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P9953

Certolizumab pegol Certolizumab; CDP870	TNF Receptor	Inflammation/Immunology Cancer
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .

HY-P99424

Afasevikumab RG 7624; RO 5553110; NI-1401	Interleukin Related	Inflammation/Immunology
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .

HY-161118

MB327	Others	Neurological Disease
MB327 is a bipyridine nonoxime compound that restores neuromuscular function. MB327 restores the activity of nicotinamide acetylcholine receptors (nAChRs) for carbachol desensitization in a typical type II PAM manner. MB327 can neutralize nerve agent poisoning .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-β Receptor	Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases .

HY-P99192

Emibetuzumab LY2875358	c-Met/HGFR	Cancer
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-160041

Olaptesed pegol	CXCR	Cancer
Olaptesed pegol (NOX-A12) L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment .

HY-P99556

Tixagevimab AZD8895	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-P99621

Fiztasovimab NPC-21; EV2038	CMV	Infection
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .

HY-149179

Polymyxin B 5+ Cited Publications	Bacterial Antibiotic	Infection
Polymyxin B is an antibiotic. Polymyxin B inhibits Gram-negative infections by binding to the LPS of the bacterial wall with high affinity. Polymyxin B neutralizes the effect of endotoxin. Polymyxin B induces bacterial death by increasing its permeability. Polymyxin B is used in endotoxemia research .

HY-B1610H

Sodium citrate dihydrate, United States Pharmacopeia (USP) Reference Standard Trisodium citrate dihydrate (Pharmaceutical primary standard, USP)	Biochemical Assay Reagents	Others
Sodium citrate dihydrate, United States Pharmacopeia (USP) Reference Standard is an antacid used in studies to neutralize gastric acid. Sodium citrate dehydrate can also be used to prepare biological buffers. Sodium citrate dehydrate is a reference standard grade of the United States Pharmacopeia (USP) and a first-class pharmaceutical standard .

HY-P99368

Lacnotuzumab MCS110; Anti-Human B7-H3	c-Fms	Metabolic Disease Cancer
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .

Cat. No.	Product Name

HY-L177

Antibody Inhibitor Library

914 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 914 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Cat. No.	Product Name	Type

HY-D0871

CHES N-Cyclohexyltaurine	Dyes
CHES (N-Cyclohexyltaurine) is a zwitterionic buffer. CHES can bind to hemagglutinin (HA) emulating with sialic acid (SA) and receptor binding site (RBS)-targeting broadly neutralizing antibodies .

Cat. No.	Product Name	Type

HY-153235

COVID-19 Spike Protein mRNA-LNP

Drug Delivery

COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein , suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

HY-107911

Protamine sulfate 1 Publications Verification	Native Proteins
Protamine sulfate, polycationic peptide and a antiheparin agent, could neutralize the anticoagulant action of heparin and enhances lipid-mediated gene transfer .

HY-D0871

CHES N-Cyclohexyltaurine	Dyes
CHES (N-Cyclohexyltaurine) is a zwitterionic buffer. CHES can bind to hemagglutinin (HA) emulating with sialic acid (SA) and receptor binding site (RBS)-targeting broadly neutralizing antibodies .

HY-Y0319B

Acetic acid potassium 99% 2 Publications Verification	Buffer Reagents
Acetic acid potassium 99% is a potassium salt employed to replenish electrolytes, for restoration of water-electrolyte balance. Acetic acid potassium 99% can employ in DNA and protein purification. Acetic acid potassium 99% has been used to prepare neutralizing solution for alkaline lysis of bacteria .

HY-B1610I

Sodium citrate dihydrate, for molecular biology Trisodium citrate dihydrate, for molecular biology	Buffer Reagents
Sodium citrate dihydrate, for molecular biology is an antacid used in studies to neutralize gastric acid. Sodium citrate dehydrate is often used to prepare biological buffers and can be used in molecular biology research .

HY-P2920

Protamine from salmon	Cell Assay Reagents
Protamine from salmon is a biochemical agent with antioxidant, antiheparin and antimicrobial activities. Protamine from salmon neutralizes the anticoagulant effect of heparin, thereby preventing the formation of antithrombin complexes in canine samples pretreated with heparin in vitro .

HY-W923277

Sodium sesquicarbonate hydrate	Buffer Reagents
Sodium sesquicarbonate hydrate is a kind of buffering agent that can stabilize pH value by neutralizing acidic substances without causing a sharp change in pH value. This property makes it widely used in many fields, especially in maintaining acid-base balance in organisms.

HY-B1610H

Sodium citrate dihydrate, United States Pharmacopeia (USP) Reference Standard Trisodium citrate dihydrate (Pharmaceutical primary standard, USP)	Buffer Reagents
Sodium citrate dihydrate, United States Pharmacopeia (USP) Reference Standard is an antacid used in studies to neutralize gastric acid. Sodium citrate dehydrate can also be used to prepare biological buffers. Sodium citrate dehydrate is a reference standard grade of the United States Pharmacopeia (USP) and a first-class pharmaceutical standard .

HY-W127447

Maleate trihydrate sodium

Maleic acid sodium

Buffer Reagents

Maleate trihydrate sodiumIt is an organic compound belonging to the salt class. It is formed from the neutralization reaction between maleic acid and sodium hydroxide and has a slightly bitter taste. Maleate trihydrate sodiumIt has a variety of applications in industrial settings, especially as an intermediate in the synthesis of various chemicals and polymers. Additionally, it is used in the food and beverage industry as a buffer, flavor enhancer and preservative.

Cat. No.	Product Name	Target	Research Area

HY-P5364

B8R 20-27	Peptides	Others
B8R 20-27 is a biological active peptide. (This is amino acids 20 to 27 fragment of B8R, a vaccinia virus (VV) gene that encodes a secreted protein related to gamma interferon receptor. B8R binding to IFN-g neutralizes its antiviral activity.)

HY-A0248

Polymyxin B Sulfate 5+ Cited Publications	Bacterial Antibiotic	Infection
Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .

HY-P2343

BH3 hydrochloride	Apoptosis	Cancer
BH3 hydrochloride, a BBB penetrated peptide, provoke apoptosis either by direct activation of pro-apoptotic Bax/Bak or by neutralizing anti-apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A-1) via their BH3 domian .

HY-P4042

Hepatitis B Virus Receptor Binding Fragment hepatitis B peptide 4980	HBV	Infection Inflammation/Immunology
Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization .

HY-P4020

2F5 epitope	HIV	Others
2F5 epitope, a peptide gp41 (659-671), comprises the entire epitope for one of the three known antibodies capable of neutralizing a broad spectrum of primary HIV-1 isolates and is the only such epitope that is sequential. 2F5 epitope is recognized by broadly neutralizing antibodies 2F5 .

HY-P5851

AaHI	Biochemical Assay Reagents	Neurological Disease
AaHI is a neurotoxin that can be obtained from the venom of the North African scorpion Androctonus australis hector. AaHI can be used as a tool for the development of active substances with toxin-neutralizing capabilities .

HY-105240

Delparantag PMX-60056	Factor Xa	Cardiovascular Disease
Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH .

HY-P4025

ELDKWA	Peptides	Others
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .

HY-P5550

Urumin	Influenza Virus	Infection
Urumin has antiviral activity against the human influenza A virus. Urumin inhibits the growth of PR8 influenza virus (IC₅₀: 3.8 μM). Urumin targets the conserved stalk of H1 hemagglutini, and is effective at neutralizing drug-resistant H1 influenza viruses. Urumin protects naive mice from lethal influenza infection .

HY-A0248R

Polymyxin B Sulfate (Standard)	Bacterial Antibiotic	Infection
Polymyxin B (Sulfate) (Standard) is the analytical standard of Polymyxin B (Sulfate). This product is intended for research and analytical applications. Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .

Cat. No.	Product Name	Target	Research Area

HY-P9945

Mepolizumab SB 240563	Interleukin Related	Cardiovascular Disease Inflammation/Immunology
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P9945A

Mepolizumab (anti-IL5)	Interleukin Related	Inflammation/Immunology
Mepolizumab (anti-IL5) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P9917

Tocilizumab Maximum Cited Publications 23 Publications Verification Anti-Human IL6R, Humanized Antibody	Interleukin Related	Inflammation/Immunology Cancer
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .

HY-P99604

Cilgavimab AZD-1061; COV2-2130	SARS-CoV	Infection
Cilgavimab (AZD-1061; COV2-2130) is a human *SARS-CoV-2*-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .

HY-P99937

Elipovimab	HIV	Infection
Elipovimab is a potent broadly neutralizing HIV-1 antibody for the targeted elimination of HIV-infected cells

HY-P99347

Etesevimab CB 6; JS016	SARS-CoV Angiotensin-converting Enzyme (ACE)	Infection
Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody .

HY-P99305

Metelimumab 1 Publications Verification CAT-192; Anti-TGFB1 Recombinant Antibody	TGF-β Receptor	Inflammation/Immunology
Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that can selectively neutralize TGFβ1 .

HY-P99584

Suvizumab KD-247	HIV	Infection
Suvizumab (KD-247) is an neutralizing antibody anti-HIV-1. Suvizumab effectively neutralizes HIV-1_MN, HIV-1_SF2 and HIV-1_89.6 with IC₅₀ values of 0.1 µg/mL, 1.0 µg/mL and 0.2 µg/mL, respectively. Suvizumab reduces the viral load of HIV. Suvizumab has good tolerance and can be used to prevent HIV infection .

HY-P99710

Lomtegovimab BI 767551; DZIF-10c	SARS-CoV	Infection
Lomtegovimab (BI 767551) is a human anti-SARS-COV-2 spike glycoprotein monoclonal antibody. Lomtegovimab binds and neutralizes SARS-CoV-2. Lomtegovimab shows antiviral efficacy. Lomtegovimab has the potential for the research of COVID-19 .

HY-P9939

Burosumab KRN23	Inhibitory Antibodies	Others Cancer
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia .

HY-P99703

Libivirumab 17.1.41	HBV	Infection
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC₅₀s of 35, 130 ng/mL for HBsAg, HBeAg, respectively .

HY-P9927

Secukinumab 1 Publications Verification AIN457	Interleukin Related	Inflammation/Immunology Cancer
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-P99307

Namilumab AMG-203; Anti-Human CSF2 Recombinant Antibody	c-Fms	Inflammation/Immunology
Namilumab (AMG203) is a human IgG1 monoclonal antibody that binds with high affinity to the GM-CSF ligand, potently neutralizing GM-CSF. Namilumab can be used for the research of rheumatoid arthritis .

HY-108739

Idarucizumab BI 655075	Inhibitory Antibodies	Cardiovascular Disease
Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .

HY-P99375

Narnatumab IMC-RON8; LY3012219; Anti-MSPR/RON/CD136 Reference Antibody (narnatumab)	Inhibitory Antibodies	Cancer
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a K_d of 32 pM. Narnatumab can be used for the research of cancer .

HY-P99469

Bentracimab PB 2452; MEDI 2452	Inhibitory Antibodies	Metabolic Disease
Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor .

HY-P99947

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

HY-P99889

Romlusevimab BRII-198	SARS-CoV	Infection
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

HY-P99900

Sevirumab MSL-109	CMV	Infection
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC₅₀ of 0.3 μg/mL .

HY-P99811

Rafivirumab CR57	RABV	Infection
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .

HY-P99792

Ormutivimab NM57; rhRIG	RABV	Infection
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .

HY-P99750

Navivumab CT-P23	Influenza Virus	Infection
Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2 .

HY-P99626

Frovocimab LY 3015014	PCSK9	Metabolic Disease
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P9953

Certolizumab pegol Certolizumab; CDP870	TNF Receptor	Inflammation/Immunology Cancer
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .

HY-P99424

Afasevikumab RG 7624; RO 5553110; NI-1401	Interleukin Related	Inflammation/Immunology
Afasevikumab (RG 7624; RO 5553110; NI-1401) is a fully human monoclonal IgG1κ antibody neutralizing both IL-17A and IL-17F. Afasevikumab has anti-inflammatory activities .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-β Receptor	Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases .

HY-P99192

Emibetuzumab LY2875358	c-Met/HGFR	Cancer
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-P99556

Tixagevimab AZD8895	SARS-CoV	Infection
Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .

HY-P99621

Fiztasovimab NPC-21; EV2038	CMV	Infection
Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV .

HY-P99368

Lacnotuzumab MCS110; Anti-Human B7-H3	c-Fms	Metabolic Disease Cancer
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .

HY-P99103

Bebtelovimab LY-3853113; LY-COV1404	SARS-CoV	Infection
Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P99756

Nirsevimab MEDI8897	RSV	Infection
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC₅₀ values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .

HY-P99277

Actoxumab Anti-C. difficile Toxin A Recombinant Antibody	Inhibitory Antibodies	Infection
Actoxumab (Anti-C. difficile Toxin A Recombinant Antibody) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab (HY-P9929) targeting TcdB .

HY-P99417

Abrezekimab UCB4144; VR 942	Interleukin Related	Inflammation/Immunology
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-P9998

Semzuvolimab UB421	HIV	Cancer
Semzuvolimab is a murine IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Murine CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection .

HY-P99529

Valziflocept BAX1810; TAK-752	Inhibitory Antibodies	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P99100

Visugromab 1 Publications Verification CTL-002	PD-1/PD-L1	Cancer
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .

HY-P9806

Anti-MERS-D12 mAb MERS-D12; MERS Antibody-D12	SARS-CoV	Infection
Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, *CD123*-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P9804

Anti-MERS-2E6 mAb MERS-2E6; MERS Antibody-2E6	SARS-CoV	Infection
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.

HY-P9949

Reslizumab Sch 55700	Interleukin Related	Inflammation/Immunology
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab has high binding affinity for human IL-5, with K_D values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively .

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-108810

Canakinumab Ilaris; ACZ 885	Interleukin Related	Inflammation/Immunology Cancer
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .

HY-P9924

Ixekizumab LY2439821	Interleukin Related	Inflammation/Immunology
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (K_D<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis .

HY-P99340

Sotrovimab 1 Publications Verification VIR 7831	SARS-CoV	Infection Cancer
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	Classification of Application Fields Disease Research Fields Cancer	EGFR Akt ERK PARP Survivin
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P9917

Tocilizumab 20+ Cited Publications Anti-Human IL6R, Humanized Antibody	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis . Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease) .

HY-B1092

Gluconate Calcium Calcium D-gluconate; Gluconic acid hemicalcium salt	Structural Classification Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields Saccharides Monosaccharides Cancer	Endogenous Metabolite
Gluconate Calcium (Calcium D-gluconate) is a mineral supplement, manufactured by the neutralization of gluconic acid with lime or calcium carbonate.

HY-D0871

CHES N-Cyclohexyltaurine	Classification of Application Fields Disease Research Fields Cancer	Biochemical Assay Reagents
CHES (N-Cyclohexyltaurine) is a zwitterionic buffer. CHES can bind to hemagglutinin (HA) emulating with sialic acid (SA) and receptor binding site (RBS)-targeting broadly neutralizing antibodies .

HY-P9939

Burosumab KRN23	Classification of Application Fields Disease Research Fields Cancer	Others
Burosumab is a human fibroblast growth factor 23 (FGF23) neutralizing antibody that can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia .

HY-P9927

Secukinumab 1 Publications Verification AIN457	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related
Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis .

HY-P9953

Certolizumab pegol Certolizumab; CDP870	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	Classification of Application Fields Disease Research Fields Cancer	TGF-β Receptor
Fresolimumab (GC1008) is a high-affinity fully human monoclonal antibody that neutralizes the active form of human TGFβ1, TGFβ2, and TGFβ3. Fresolimumab can be used for the research of cancer and fibrotic diseases .

HY-P99192

Emibetuzumab LY2875358	Classification of Application Fields Disease Research Fields Cancer	c-Met/HGFR
Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab shows high neutralization and internalization activities, resulting in inhibition of both HGF-dependent and HGF-independent MET pathway activation and tumor growth. Emibetuzumab can be used in study of cancer .

HY-P99368

Lacnotuzumab MCS110; Anti-Human B7-H3	Classification of Application Fields Disease Research Fields Cancer	c-Fms
Lacnotuzumab (MCS110) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1 that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis .

HY-A0248

Polymyxin B Sulfate 5+ Cited Publications	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Mammalian Cell Culture Antibacterial Disease Research Disease Research Fields Other Antibiotics	Bacterial Antibiotic
Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .

HY-P99100

Visugromab 1 Publications Verification CTL-002	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, *CD123*-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-108810

Canakinumab Ilaris; ACZ 885	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC₅₀ values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .

HY-P99340

Sotrovimab 1 Publications Verification VIR 7831	Classification of Application Fields Disease Research Fields Cancer	SARS-CoV
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

HY-A0248R

Polymyxin B Sulfate (Standard)	Structural Classification Microorganisms Antibiotics Source classification Mammalian Cell Culture Antibacterial Disease Research Other Antibiotics	Bacterial Antibiotic
Polymyxin B (Sulfate) (Standard) is the analytical standard of Polymyxin B (Sulfate). This product is intended for research and analytical applications. Polymyxin B Sulfate is a potent antibacterial agent and a relatively toxic antibiotic. Polymyxin B Sulfate also is a antiendotoxin agent. Polymyxin B Sulfate shows endotoxin-neutralizing properties can be used as adjunctive research in gram-negative sepsis. Polymyxin B Sulfate shows antibacterial activities in vitro and in vivo .

HY-B0215

Acetylcysteine Maximum Cited Publications 389 Publications Verification N-Acetylcysteine; N-Acetyl-L-cysteine; NAC	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reactive Oxygen Species Endogenous Metabolite Apoptosis Ferroptosis Influenza Virus Disulfidptosis
Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .

HY-B0215R

Acetylcysteine (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reactive Oxygen Species Endogenous Metabolite Apoptosis Ferroptosis Influenza Virus Disulfidptosis
Acetylcysteine (Standard) is the analytical standard of Acetylcysteine. This product is intended for research and analytical applications. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor . Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases . Acetylcysteine induces cell apoptosis . Acetylcysteine also has anti-influenza virus activities . In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .

Cat. No.	Product Name	Chemical Structure

HY-100561S

Tempol-d17,15N
Tempol-d₁₇, ¹⁵N is the deuterium labeled Tempol[1]. Tempol is a general superoxide dismutase (SOD)-mimetic agent that efficiently neutralizes reactive oxygen species (ROS)[2][3].

HY-100561S1

Tempol-d17
Tempol-d₁₇ is the deuterium labeled Tempol[1]. Tempol is a general superoxide dismutase (SOD)-mimetic agent that efficiently neutralizes reactive oxygen species (ROS)[2][3].

HY-B0215S

Acetylcysteine-d3

Acetylcysteine-d₃ is the deuterium labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .

HY-B0215S1

Acetylcysteine-15N

Acetylcysteine- ¹⁵N (N-Acetylcysteine- ¹⁵N) is the ¹⁵N-labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .

Cat. No.	Product Name		Classification

HY-153235

COVID-19 Spike Protein mRNA-LNP		mRNA
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein , suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 Spike Protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 Spike Protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

HY-153480A

ARC19499 sodium BAX499 sodium		Aptamers
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-F0003

NADPH tetrasodium salt 5+ Cited Publications		Nucleotides and their Analogs
NADPH tetrasodium salt functions as an important cofactor in a variety of metabolic and biosynthetic pathways. NADPH tetrasodium salt plays a vital role in the biosynthesis of agents, chiral alcohols, fatty acids and biopolymers, while also being required for lipid biosynthesis, biomass formation, and cell replication. The demand for NADPH tetrasodium salt is particularly high in proliferating cancer cells, where it acts as a cofactor for the synthesis of nucleotides, proteins, and fatty acids. NADPH tetrasodium salt is also essential for the neutralization of the dangerously high levels of reactive oxygen species (ROS) generated by increased metabolic activity. NADPH tetrasodium salt is an endogenous inhibitor of ferroptosis .

HY-153083

COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)		mRNA
COVID-19 Spike Protein mRNA will express COVID-19 spike protein, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design .

HY-160041A

Olaptesed pegol sodium		Antisense Oligonucleotides
Olaptesed pegol sodium A pegylated-based L-oligoribonucleotide aptamer targeting CXCL12. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment .

HY-160041

Olaptesed pegol		Antisense Oligonucleotides
Olaptesed pegol (NOX-A12) L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment .

HY-153480

ARC19499 BAX499		Aptamers
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

neutralization

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products